NCT06979609 (SPORES-V) is a Phase 2, PHASE3 clinical trial of Oral Vancomycin Prophylaxis in Clostridioides Difficile Infection, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre.

What drugs are being tested in NCT06979609?

Interventions in NCT06979609: Oral Vancomycin Prophylaxis, Placebo.

What condition does NCT06979609 study?

NCT06979609 studies Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Clostridoides Difficile Associated Disease.

Is NCT06979609 still recruiting?

NCT06979609 is currently recruiting now. Last updated 19 September 2025.

Last reviewed 2025-09-19 · How we verify

NCT06979609: SPORES-V

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Secondary Prevention of Clostridioides Difficile Using Vancomycin

Recruiting now Phase 2, PHASE3 Last updated 19 September 2025

What this trial tests

Phase 2, PHASE3 trial testing Oral Vancomycin Prophylaxis in Clostridioides Difficile Infection in 300 participants. Currently enrolling.

Timeline

1 October 2025

Primary endpoint
1 October 2028

1 October 2029

Quick facts

Lead sponsor	McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase	Phase 2, PHASE3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	300
Start date	1 October 2025
Primary completion	1 October 2028
Estimated completion	1 October 2029
Sites	1 location across Canada

Drugs / interventions tested

Oral Vancomycin Prophylaxis — full drug profile →
Placebo

Conditions studied

Clostridioides Difficile Infection — all drugs for Clostridioides Difficile Infection →
Clostridioides Difficile Infection Recurrence — all drugs for Clostridioides Difficile Infection Recurrence →
Clostridoides Difficile Associated Disease — all drugs for Clostridoides Difficile Associated Disease →

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Who can join

18 and older, any sex, with Clostridioides Difficile Infection or Clostridioides Difficile Infection Recurrence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Re-exposure to systemic antibiotics (i.e., antibiotics absorbed into the bloodstream) is common after a Clostridioides difficile infection (CDI) and is the strongest risk factor for a recurrent episode. Oral vancomycin to prevent a recurrence during antibiotic re-exposure may reduce this risk but the data supporting this practice are limited. The aim of this trial is: 1\) Does oral vancomycin prophylaxis prevent CDI recurrences in patients with recent CDI (within 120 days) and who are re-exposed to systemic antibiotics? The trial will compare oral vancomycin to placebo. Participants will: * Take the study drug (either vancomycin or placebo) twice daily for the duration of systemic antibiotics plus once daily for 7 days after completion of systemic antibiotics. * Attend an in-person follow-up at day 56 * Respond to weekly electronic questionnaires

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Clostridioides Difficile Infection

Currently open trials in the same condition.

NCT07285213 — Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody · Phase 2 · recruiting
NCT06859437 — Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain in Nephrology and Transplantati · NA · recruiting
NCT05330182 — LMN-201 for Prevention of C. Difficile Infection Recurrence · Phase 2, PHASE3 · recruiting
NCT06788769 — Study of Clostridioides Difficile in Infants · recruiting
NCT06306014 — Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in Hi · Phase 1, PHASE2 · recruiting

Other McGill University Health Centre/Research Institute of the McGill University Health Centre trials

Trials by the same sponsor.

NCT07439406 — Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy · Phase 2 · not yet recruiting
NCT07328971 — Vancomycin Taper to Prevent Recurrent Clostridioides Difficile · Phase 3 · not yet recruiting
NCT07556952 — Dex & Mastectomy Pain · Phase 4 · recruiting
NCT07069582 — Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women · Phase 1 · not yet recruiting
NCT07386171 — Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06979609 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by McGill University Health Centre/Research Institute of the McGill University Health Centre
Last refreshed: 19 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06979609.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing